about
Using wastewater-based epidemiology to estimate drug consumption-Statistical analyses and data presentation.Risk factors for nonfatal overdose at Seattle-area syringe exchanges.Prescription long-term opioid use in HIV-infected patientsThe spatial epidemiology of cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) use: a demonstration using a population measure of community drug load derived from municipal wastewater.Wastewater testing compared with random urinalyses for the surveillance of illicit drug use in prisonsConcurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors.Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer painNormalized diurnal and between-day trends in illicit and legal drug loads that account for changes in population.Problematic use of prescription-type opioids prior to heroin use among young heroin injectors.Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients.Substance use, treatment admissions, and recovery trends in diverse Washington State tribal communitiesOpioid use behaviors, mental health and pain--development of a typology of chronic pain patients.Police officers' and paramedics' experiences with overdose and their knowledge and opinions of Washington State's drug overdose-naloxone-Good Samaritan law.Who prescribes buprenorphine for rural patients? The impact of specialty, location and practice type in Washington State.Heroin and pharmaceutical opioid overdose events: Emergency medical response characteristics.Working upstream: how far can you go with sewage-based drug epidemiology?Health behaviors of young adult heroin injectors in the Seattle area.Opioid use disorder and misuse: A review of the epidemiology and medical implications for pediatric anesthesiologists.Eliminating solid phase extraction with large-volume injection LC/MS/MS: analysis of illicit and legal drugs and human urine indicators in U.S. wastewaters.An Initial Evaluation of Web-Based Opioid Overdose Education.Intranasal Naloxone for Opioid Overdose Reversal.Correction to Normalized Diurnal and Between-Day Trends in Illicit and Legal Drug Loads that Account for Changes in Population.Commentary on Pierce et al. (2016): Raising the bar of addiction treatment--first do no harm.Epidemiology of MDMA and associated club drugs in the Seattle area.Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington.The need for better marijuana sales data.Impacts of an opioid overdose prevention intervention delivered subsequent to acute care.Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'."Hooked on" prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients.A Comprehensive Approach to Address the Prescription Opioid Epidemic in Washington State: Milestones and Lessons LearnedInterpreting methamphetamine levels in a high-use communityAdolescent abuse of pharmaceutical opioids raises questions about prescribing and preventionAge and gender trends in long-term opioid analgesic use for noncancer painThe Changing Burden of HIV Attributable to Methamphetamine Among Men Who Have Sex with Men in King County, WashingtonInterest in Getting Help to Reduce or Stop Substance Use Among Syringe Exchange Clients Who Use OpioidsOpioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility StudyDevelopment of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA)The projected costs and benefits of a supervised injection facility in Seattle, WA, USAEngaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, WashingtonThe dueling obligations of opioid stewardship
P50
Q31110335-338CF728-CD05-4C49-9545-28B6A457DE81Q34588009-B5DF0B3B-5772-47FD-BBE2-72C3B2EDAB28Q35219167-36407363-F4AD-410A-B715-C1231DABA823Q35576210-24396044-6B5E-4571-9D0E-624BD4408CB9Q35736131-82F7DE9B-9047-45E0-B839-D45EFA0F237DQ35803135-AE334FBD-D82F-4B3F-A7C5-12E9A6E4FF83Q35868840-ACAD3170-6C4E-415F-9E9B-9B21008276FFQ36290813-236E73F3-538E-4C0A-8669-D918CA006FFCQ36505814-2BE26400-1E1D-42AF-881B-BAF7ABF9FE35Q36880782-F240B899-B048-469B-B9C4-3C183951D59BQ37079139-DE8176F3-BF1D-4152-9E7E-C7739BD72832Q37276433-7B5550F5-96EE-4080-BDB2-3B2728D5E65DQ37368415-DBB22371-081A-4433-92E4-1E552B70D353Q37455780-DCEF4249-EA36-47EF-AB26-41EB5F6AA500Q38721421-62D23AB1-F3FC-4542-B54F-06164676AC9CQ39293365-67158254-8DDB-4862-9599-A7DFFC00CC6EQ41063883-B2691020-6930-4932-B506-A0DFF9946D95Q43075789-03A66024-AA0D-462B-B258-744F213A63E0Q43367615-35AB174F-2064-4BEF-8758-13A989372780Q44334331-ECA27542-C28B-4ACB-9B66-F48E42CC6C0AQ44346658-2F69C694-B948-4B11-8C13-C5A168FD6E2EQ45851881-C7E77F5F-EB24-47D8-A4C3-EC1D7F879B97Q46049740-E5480223-85B6-4B95-8183-6C634BEE0881Q46622348-CB60CA16-284E-48D6-9AAF-84B49FA0692AQ47413952-C1312FF7-E84E-4CA7-8C3D-448725B73192Q47653433-6CBD00A1-5087-44DB-9A63-FFD43429F3F8Q50045157-1ED61175-00F2-4652-BBC2-34627B5EC758Q50224080-61CB66B4-48DD-4205-A5B2-B334A2E131F4Q52301622-75C89626-776A-4F20-A34D-E516AD8138BFQ64126733-F39F67C3-E510-4786-9FAF-64BBCE4EAE8AQ83920571-02EF3C56-2C45-45C5-A658-4294D261D6EAQ84081018-EEC594AE-616F-4EE5-BC9F-330307A31FA4Q84774194-FA3F0006-C400-4E7F-A26F-AA9F1647653DQ88932328-C61C6D70-0065-4B3E-8FC7-673290E3D110Q89060803-7F7EAA60-465C-4796-8A80-2658562024D8Q91153746-58A5FC91-44EB-4990-9304-32B843065A81Q91440022-144381FA-D9C6-4604-9AE9-B3487F88022DQ91894073-8DDB81F5-3760-410C-B708-D2741C72323EQ92563181-73ED2BFE-CE5A-4543-9CD3-C0483DA5EE1BQ95487372-798BA403-3EA1-46BC-8503-CA00DAFCC3E4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Caleb Banta-Green
@en
Caleb Banta-Green
@nl
type
label
Caleb Banta-Green
@en
Caleb Banta-Green
@nl
prefLabel
Caleb Banta-Green
@en
Caleb Banta-Green
@nl
P31
P496
0000-0003-4084-6943